isobutyryl-1-carnitine profile

O-isobutyryl-L-carnitine : An optically active form of O-isobutyrylcarnitine having (R)-configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	168379
CHEBI ID	84838
SCHEMBL ID	677165
MeSH ID	M0074035

Synonym
25518-49-4
ammonium, (3-carboxy-2-hydroxypropyl)trimethyl-, hydroxide, inner salt, isobutyrate, l-
1-propanaminium, 3-carboxy-n,n,n-trimethyl-2-(2-methyl-1-oxopropoxy)-, inner salt, (r)-
iso-butyryl-l(-)-carnitin [german]
brn 4138517
isobutyryl-l-carnitine
isobutyryl-1-carnitine
isobutyryl-carnitine
(s)-3-carboxy-n,n,n-trimethyl-2-(2-methyl-1-oxopropoxy)-1-propanaminium, hydroxide, inner salt
(3r)-3-(2-methylpropanoyloxy)-4-(trimethylazaniumyl)butanoate
o-isobutanoyl-(r)-carnitine
CHEBI:84838
o-isobutyryl-l-carnitine
isobutyryl-l-(-)-carnitine
(r)-isobutyrylcarnitine
(3r)-3-[(2-methylpropanoyl)oxy]-4-(trimethylazaniumyl)butanoate
g962k8pxu5 ,
unii-g962k8pxu5
iso-butyryl-l(-)-carnitin
isobutyrylcarnitine
SCHEMBL677165
isobutyryl-l-carnitine, >=97.0% (tlc)
AS-70920
l-isobutyric acid ester with (3-carboxy-2-hydroxypropyl)trimethylammonium hydroxide inner salt
Q27158106
CS-0062326
HY-113165
(3r)-3-(2-methylpropanoyloxy)-4-trimethylazaniumylbutanoate
DTXSID70948420
AKOS037646806
1-propanaminium, 3-carboxy-n,n,n-trimethyl-2-(2-methyl-1-oxopropoxy)-, inner salt, (2r)-

Role	Description
human metabolite	Any mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
O-isobutyrylcarnitine	An O-acylcarnitine having isobutyryl as the acyl substituent.
methyl-branched fatty acyl-L-carnitine	An O-acylcarnitine in which the R group is a methyl-branched fatty acyl chain.
saturated fatty acyl-L-carnitine	An O-acylcarnitine in which the R is a saturated fatty acyl chain.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2 (16.67)	18.7374
1990's	2 (16.67)	18.2507
2000's	2 (16.67)	29.6817
2010's	1 (8.33)	24.3611
2020's	5 (41.67)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	2 (16.67%)	4.05%
Observational	0 (0.00%)	0.25%
Other	10 (83.33%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
carnitine [no description available]	3.72	10	amino-acid betaine	human metabolite; mouse metabolite
glutaric acid glutaric acid: RN given refers to parent cpd. glutaric acid : An alpha,omega-dicarboxylic acid that is a linear five-carbon dicarboxylic acid.	1.97	1	alpha,omega-dicarboxylic acid; dicarboxylic fatty acid	Daphnia magna metabolite; human metabolite
metformin Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.	2.25	1	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic
aspartic acid Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid.	2.6	1	aspartate family amino acid; aspartic acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; mouse metabolite; neurotransmitter
leucine Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.	1.97	1	amino acid zwitterion; L-alpha-amino acid; leucine; proteinogenic amino acid; pyruvate family amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
valine Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.	1.99	1	L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid; valine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
ethylmalonic acid ethylmalonic acid: don't confuse with diethyl malonate, which is a diester. ethylmalonate : A dicarboxylic acid anion obtained by deprotonation of at least one of the carboxy groups of ethylmalonic acid.. ethylmalonic acid : A dicarboxylic acid obtained by substitution of one of the methylene hydrogens of malonic acid by an ethyl group.	2.03	1	dicarboxylic acid; dicarboxylic fatty acid	human metabolite
s-adenosylmethionine acylcarnitine: structure in first source. S-adenosyl-L-methioninate : A sulfonium betaine that is a conjugate base of S-adenosyl-L-methionine obtained by the deprotonation of the carboxy group.	2.53	2	sulfonium betaine	human metabolite
coenzyme a [no description available]	2.41	1	adenosine 3',5'-bisphosphate	coenzyme; Escherichia coli metabolite; mouse metabolite
butyrylcarnitine butyrylcarnitine: structure in first source. O-butanoyl-L-carnitine : An optically active form of O-butanoylcarnitine having L-configuration.. O-butanoylcarnitine : A C4-acylcarnitine that is the O-butanoyl derivative of carnitine.	2.97	4	O-butanoylcarnitine; saturated fatty acyl-L-carnitine	metabolite
3-methylbutyrylcarnitine 3-methylbutyrylcarnitine: affects 2-oxo acid dehydrogenase activity in intact mitochondria of rat muscle; RN given refers to (R)-isomer. O-isovalerylcarnitine : A C5-acylcarnitine having isovaleryl as the acyl substituent.	2.67	3	C5-acylcarnitine	human metabolite
glutarylcarnitine glutarylcarnitine: found in glutaric aciduria type 1	2.44	2	O-acylcarnitine
pivaloylcarnitine O-pivaloylcarnitine : A C5-acylcarnitine in which the acyl group specified is pivaloyl.	2.05	1	C5-acylcarnitine	metabolite

Condition	Relationship Strength	Studies
Autosomal Dominant Juvenile Parkinson Disease [description not available]	2.31	1
Prodromal Characteristics [description not available]	2.31	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.31	1
Parkinsonian Disorders A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.	2.31	1
Apoplexy [description not available]	2.6	1
Infarct, Lacunar [description not available]	2.6	1
Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)	2.6	1
Inborn Errors of Metabolism [description not available]	2.01	1
Metabolism, Inborn Errors Errors in metabolic processes resulting from inborn genetic mutations that are inherited or acquired in utero.	2.01	1
Brain Disorders [description not available]	2.03	1
Nervous System Disorders [description not available]	2.03	1
Brain Diseases Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.	2.03	1
Nervous System Diseases Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.	2.03	1
Cardiomyopathies, Primary [description not available]	1.99	1
Cardiomyopathies A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).	1.99	1
Amino Acid Metabolism Disorders, Inborn [description not available]	1.97	1
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	1.97	1

isobutyryl-1-carnitine

Description

Cross-References

Synonyms (31)

Roles (1)

Drug Classes (3)

Research

Studies (12)

Market Indicators

Research Demand Index: 12.76

Study Types